| Paris | |
| 198 | |
| Nanobiotix develops innovative nanoparticle technology dedicated to the local treatment of cancer. Its nanoparticles interact with radiotherapy and maximize the effect of radiotherapy within tumors. | |
| NBTXR3 nanoparticles are designed for direct injection into the tumor. The initial indications for NBTXR3 are primary liver cancer, glioblastoma (a specific form of brain cancer), rectal cancer, prostate cancer or head and neck cancers. NBTXR3 is currently clinically tested in patients with soft tissue sarcoma. NBTX-IV nanoparticles are designed for intravenous injection so that the product can reach the tumor and also the surrounding tissue which may be already invaded locally by cancer cells. This may not only lead to increased tumor destruction but may also reduce the subsequent escape of malignant cells localized in neighboring lymph nodes. Targeted indications are advanced stage tumors that have invaded surroundings lymph nodes, such as rectal cancers, locally advanced prostate cancer or lung carcinoma. NBTX-TOPO nanoparticles are formulated as a gel to be applied during surgery after removal of the tumor. The product is intended in particular for different types of breast cancer, brain tumors and retroperitoneal soft tissue sarcomas. NBTX-TOPO may be used to delineate the tumor in CT scans and to prepare the tumor bed for postoperative radiotherapy. NBTXR3, NBTX-IV and NBTX-TOPO are designed to improve anti-cancer treatment of a large number of patients with solid tumors currently treated with radiotherapy (or patients who cannot be treated this way because of their elevated radiosensitivity). The combined use of nanoparticles with radiotherapy will lead to personalized anti-cancer therapy, optimally adapted to the particular features of the tumor in question. |
|
| MAUBERNA Philippe | |
| www.nanobiotix.com | |
| NANO:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 23 fois.